Article
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Oncogene - 1 May 2018
Cannataro Vincent L, Gaffney Stephen G, Stender Carly, Zhao Zi-Ming, Philips Mark, Greenstein Andrew E, Townsend Jeffrey P
Abstract excerpt
Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant. However, concerns exist regarding the effectiveness of such therapies in vivo given the possibilities of existing intratumor heterogeneity or de novo mutation leading to treatment resistance. We performed deep sequencing of 27 KRAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.